Widgetized Section

Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone

Mylan deal clears path for biosimilar copy of Roche's Herceptin

Published Monday March 13

Herceptin, which generated sales of 6.78 billion Swiss francs in 2016, is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years.

…price biosimilars as it looks to new medicines to drive future growth. Roche also faces biosimilar competition to its blood cancer drug Rituxan, with the first such rival launching in Europe last month.

Article length: About 170 words.
Tags: Patented Deal Sell Sale
Read more at Channelnewsasia